JP2015504094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504094A5 JP2015504094A5 JP2014553457A JP2014553457A JP2015504094A5 JP 2015504094 A5 JP2015504094 A5 JP 2015504094A5 JP 2014553457 A JP2014553457 A JP 2014553457A JP 2014553457 A JP2014553457 A JP 2014553457A JP 2015504094 A5 JP2015504094 A5 JP 2015504094A5
- Authority
- JP
- Japan
- Prior art keywords
- sialic acid
- composition
- release formulation
- extended release
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 43
- 238000009472 formulation Methods 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 229920000642 polymer Polymers 0.000 claims description 15
- 230000036470 plasma concentration Effects 0.000 claims description 10
- 206010028640 Myopathy Diseases 0.000 claims description 6
- 208000009640 Nonaka type Distal myopathy Diseases 0.000 claims description 6
- 201000008319 inclusion body myositis Diseases 0.000 claims description 6
- 201000010770 muscular disease Diseases 0.000 claims description 6
- 201000009623 myopathy Diseases 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 230000035839 C max Effects 0.000 claims description 4
- 229940113118 Carrageenan Drugs 0.000 claims description 4
- 229940005550 Sodium alginate Drugs 0.000 claims description 4
- 230000037098 T max Effects 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 239000007891 compressed tablet Substances 0.000 claims description 4
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 230000001419 dependent Effects 0.000 claims description 3
- 239000000416 hydrocolloid Substances 0.000 claims description 3
- 230000035888 Maximum plasma concentration Effects 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 235000020937 fasting conditions Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 208000008425 Protein Deficiency Diseases 0.000 claims 3
- 210000003934 Vacuoles Anatomy 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000007688 edging Methods 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 210000003802 Sputum Anatomy 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261588069P | 2012-01-18 | 2012-01-18 | |
| US61/588,069 | 2012-01-18 | ||
| US201261709549P | 2012-10-04 | 2012-10-04 | |
| US61/709,549 | 2012-10-04 | ||
| PCT/US2013/022167 WO2013109906A2 (fr) | 2012-01-18 | 2013-01-18 | Procédés et formulations permettant de traiter les déficiences en acide sialique |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017141883A Division JP2017186381A (ja) | 2012-01-18 | 2017-07-21 | シアル酸欠乏を処置するための方法および製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504094A JP2015504094A (ja) | 2015-02-05 |
| JP2015504094A5 true JP2015504094A5 (fr) | 2015-11-12 |
Family
ID=48799814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553457A Pending JP2015504094A (ja) | 2012-01-18 | 2013-01-18 | シアル酸欠乏を処置するための方法および製剤 |
| JP2017141883A Pending JP2017186381A (ja) | 2012-01-18 | 2017-07-21 | シアル酸欠乏を処置するための方法および製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017141883A Pending JP2017186381A (ja) | 2012-01-18 | 2017-07-21 | シアル酸欠乏を処置するための方法および製剤 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2804600A4 (fr) |
| JP (2) | JP2015504094A (fr) |
| KR (1) | KR20150000872A (fr) |
| CN (1) | CN104271125A (fr) |
| AU (1) | AU2013209610B2 (fr) |
| BR (1) | BR112014017587A8 (fr) |
| CA (1) | CA2862836A1 (fr) |
| IL (1) | IL233225A0 (fr) |
| WO (1) | WO2013109906A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9241896B2 (en) | 2008-12-19 | 2016-01-26 | Ultragenyx Pharmaceutical Inc. | Methods and formulations for treating sialic acid deficiencies |
| EP2593109A4 (fr) | 2010-07-13 | 2014-01-08 | Ultragenyx Pharmaceutical Inc | Méthode et formulations destinées au traitement de déficiences en acide sialique |
| WO2013063149A1 (fr) | 2011-10-24 | 2013-05-02 | Ultragenyx Pharmaceutical, Inc. | Analogues de l'acide sialique |
| WO2017048817A1 (fr) | 2015-09-14 | 2017-03-23 | Ultragenyx Pharmaceutical Inc. | Formes cristallines d'acide sialique ou sel ou solvate de celles-ci |
| EP3486326A1 (fr) | 2017-11-21 | 2019-05-22 | Jennewein Biotechnologie GmbH | Procédé de purification d'acide n-acétylneuraminique à partir d'un bouillon de fermentation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008150477A2 (fr) * | 2007-05-31 | 2008-12-11 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Mannosamine de n-acétyle en tant qu'agent thérapeutique |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| JP5626734B2 (ja) * | 2009-05-15 | 2014-11-19 | 公益財団法人ヒューマンサイエンス振興財団 | Ｇｎｅタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物 |
| EP2593109A4 (fr) * | 2010-07-13 | 2014-01-08 | Ultragenyx Pharmaceutical Inc | Méthode et formulations destinées au traitement de déficiences en acide sialique |
| WO2013063149A1 (fr) * | 2011-10-24 | 2013-05-02 | Ultragenyx Pharmaceutical, Inc. | Analogues de l'acide sialique |
-
2013
- 2013-01-18 CA CA2862836A patent/CA2862836A1/fr not_active Abandoned
- 2013-01-18 JP JP2014553457A patent/JP2015504094A/ja active Pending
- 2013-01-18 AU AU2013209610A patent/AU2013209610B2/en not_active Expired - Fee Related
- 2013-01-18 EP EP13739040.7A patent/EP2804600A4/fr not_active Withdrawn
- 2013-01-18 CN CN201380015020.XA patent/CN104271125A/zh active Pending
- 2013-01-18 BR BR112014017587A patent/BR112014017587A8/pt not_active Application Discontinuation
- 2013-01-18 KR KR1020147022912A patent/KR20150000872A/ko not_active Application Discontinuation
- 2013-01-18 WO PCT/US2013/022167 patent/WO2013109906A2/fr active Application Filing
-
2014
- 2014-06-18 IL IL233225A patent/IL233225A0/en unknown
-
2017
- 2017-07-21 JP JP2017141883A patent/JP2017186381A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| US20240082231A1 (en) | Niraparib formulations | |
| ES2823000T3 (es) | Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas | |
| JP2015504094A5 (fr) | ||
| JP2016512248A5 (fr) | ||
| JP5918242B2 (ja) | リファキシミンを含む医薬処方物、それを得るための方法及び腸疾患を治療する方法 | |
| JP2016503030A5 (fr) | ||
| JP2017514850A5 (fr) | ||
| FI3902547T3 (fi) | Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| JP2012193216A5 (fr) | ||
| WO2016210003A3 (fr) | Compositions orales contenant un ester de 17-hydroxyprogestérone et procédés s'y rapportant | |
| JP2017528497A5 (fr) | ||
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| JP2016512247A5 (fr) | ||
| JP2015531749A5 (fr) | ||
| JP2016520114A5 (fr) | ||
| JP2017507142A5 (fr) | ||
| JP2017512194A5 (fr) | ||
| WO2012020301A3 (fr) | Compositions orales de blonanserin à libération contrôlée | |
| EP3210599A1 (fr) | Formulation gastro-résistante contenant du posaconazole et un inhibiteur de précipitation polymère | |
| JP2017508455A5 (fr) | ||
| JP2016514706A5 (fr) | ||
| WO2014006571A2 (fr) | Formes galéniques pharmaceutiques à libération prolongée de carbidopa et de lévodopa et leurs procédés de préparation |